Recently, the Revvity NeoBase2 non-derivatized MS/MS kit introduced ADO measurement, enabling the screening of adenosine deaminase (ADA) deficiency and expanding the scope of neonatal metabolic disorder screening [6,7]. Here, ADA is linked to metabolic disease.